Mayank Mamtani from B.Riley Financial issued a price target of $83.00 for CUE on 2026-10-01 09:03:00.The adjusted price target was set to $83.00.At the time of the announcement, CUE was trading at $25.87.The overall price target consensus is at $4.33 with high price of $7.00, low price of $2.00, and median price is at $4.00.CUE...
H.C. Wainwright analyst issues BUY recommendation for PRQR on October 1, 2026 10:54AM ET. The previous...
Citigroup analyst issues OUTPERFORM recommendation for SGMT on October 1, 2026 09:44AM ET. The previous analyst...
Citigroup analyst issues MARKET OUTPERFORM recommendation for SGMT on October 1, 2026 08:17AM ET. The previous...
Citigroup analyst issues MARKET OUTPERFORM recommendation for PRQR on October 1, 2026 08:14AM ET. The previous...
Mayank Mamtani from B.Riley Financial issued a price target of $83.00 for CUE on 2026-10-01 09:03:00.The adjusted price target was set to $83.00.At the time of the announcement, CUE was...
Josh Nichols from B.Riley Financial issued a price target of $27.00 for OOMA on 2026-09-30 16:08:00.The adjusted price target was set to $27.00.At the time of the announcement, OOMA was...
from D.A. Davidson issued a price target of $15.00 for PAYS on 2026-09-30 12:13:47.The adjusted price target was set to $15.00.At the time of the announcement, PAYS was trading at...
Andrea Newkirk from Goldman Sachs issued a price target of $103.00 for KOD on 2026-09-30 01:00:16.The adjusted price target was set to $103.00.At the time of the announcement, KOD was...
from Stifel Nicolaus issued a price target of $18.00 for ACHV on 2026-09-29 20:15:49.The adjusted price target was set to $18.00.At the time of the announcement, ACHV was trading at...
In a landscape marked by rapid technological advancements, the company saw a revenue increase of $1.4 million for the three months ending September 30, 2024, fueled by new licenses and...
In a landscape of fluctuating revenues, the company celebrated a 25% revenue increase in Q3 2024, yet faced a 14% decline over nine months due to production challenges. Operating expenses...
In a landscape marked by financial challenges, the company faced fluctuating revenues, with a notable 25% increase in Q3 2024 overshadowed by a 14% decline over nine months. Operating losses...
In a tale of growth and ambition, the company witnessed its revenue soar from $6.0 million to $13.9 million, fueled by partnerships with Acadia Pharmaceuticals. However, operating expenses, particularly in...
In a transformative period, the company experienced a remarkable surge in revenue, driven by newly acquired oil and gas assets. Operating expenses showed notable trends, with a decrease in occupancy...
